Project Grant 2437939
Award Date 10/1/25
Completion Date 9/30/26
Dollars Obligated $305K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cumming, GA, USA
Similar Awards
- This STTR Phase I project, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a novel vaccine platform to provide longer-lasting protection against infectious diseases. The $304,438 grant, awarded on October 1, 2025, supports Nitro Biosciences Inc.'s research to overcome limitations associated with immune imprinting, where prior exposure to pathogens can bias immune responses away from protective...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...
- This STTR Phase I project by Immuno Nano Med, Inc. was awarded a $305,000 grant from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to demonstrate the feasibility of producing a novel room-temperature-stable, dry-powder inhalable influenza vaccine, replacing current needle-based flu shots that require refrigerated storage. This innovative vaccine technology has the potential to significantly lower storage costs, improve...
- The National Science Foundation awarded Diant Pharma Inc. a $256,000 Project Grant under the Engineering (47.041) federal grant program. The grant will support development of an advanced continuous manufacturing system for nucleic acid lipid nanoparticles to improve supply chains for therapeutics and vaccines. Specifically, the small business innovation research Phase I project aims to create a compact, end-to-end manufacturing platform that follows current good manufacturing practices. This...
- This SBIR Phase I project, funded by the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a microneedle-based platform for the treatment of autoimmune skin diseases. The $304,450 award to Lybra Bio Inc. in Cambridge, MA will advance the hydrogel-based microneedle patch technology to achieve scale-up readiness. The goal is to modulate the drug release profile and determine the minimum wear time required for therapeutic...
- The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...
- The National Science Foundation (NSF) awarded a $274,438 SBIR Phase I grant to Script Biosciences Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project, titled "CASPLUS: A Safer, More Efficient, and Targeted Method of Deploying CRISPR In Vivo," aims to develop a platform technology that significantly reduces the potential inaccuracy of current gene editing techniques. The innovation targets the desired gene, increasing the safety and efficacy of...
- This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
- This SBIR Phase I federal grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $305,000 to Plexymer, Inc. to develop an AI-directed automation platform for accelerated bioformulation of antibody therapeutics. The project aims to streamline the process of transitioning hospital-administered antibody infusions to self-administered subcutaneous injections, potentially reducing formulation time and material use by up to 50%. By...
- The National Science Foundation (NSF) awarded a Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Femtofluidics Incorporated for $294,932 on January 1, 2025. The purpose of this SBIR Phase I award is to develop hardware that enables the rapid and inexpensive synthesis of DNA-encoded libraries (DELs). This technology aims to accelerate drug discovery by expediting the identification of drug candidates for challenging diseases and generating data to...